Fuzeon Plus Active Protease Inhibitor Shows Maximal HIV Suppression

Patients previously treated with three classes of antiretrovirals can achieve maximal viral suppression when starting a regimen of Fuzeon in combination with an active boosted protease inhibitor and other anti-HIV drugs, according to new study data.

These new studies add to the growing body of evidence that support a powerful treatment strategy for treatment-experienced patients -- building upon findings from the Fuzeon (enfuvirtide) pivotal trials, TORO-1 and TORO-2. Co-developed by Roche and Trimeris, Fuzeon is the first and only fusion inhibitor available for the treatment of HIV.